ConductScience.org, home

Paper39796708

Molecular Basis of Oncogenic PI3K Proteins.

Sheng Z and 4 others. Cancers (Basel), 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Molecular Basis of Oncogenic PI3K Proteins. Papers, record 39796708. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796708

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Molecular Basis of Oncogenic PI3K Proteins.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.71, provisional
iCite
Revised in PubMed
2025-02-12
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sheng ZZhihttps://orcid.org/0000-0002-0029-8666
2Beck PPatrick
3Gabby MMaegan
4Habte-Mariam SSemhar
5Mitkos KKatherine

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R21 CA245631NCI NIH HHSUnited StatesR21CA245631PubMedNIH RePORTER
R21 CA289124NCI NIH HHSUnited StatesR21CA289124PubMedNIH RePORTER
R21CA289124NCI NIH HHSUnited StatesR21CA289124PubMedNIH RePORTER
R21CA245631NCI NIH HHSUnited StatesR21CA245631PubMedNIH RePORTER

Download CSV of grants

References166

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128630349PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.Proc Natl Acad Sci U S A2017https://conductscience.org/library/papers/28630349PubMed
219915146Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.Proc Natl Acad Sci U S A2009https://conductscience.org/library/papers/19915146PubMed
311090628Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.Mol Cell2000https://conductscience.org/library/papers/11090628PubMed
428676499Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.J Biol Chem2017https://conductscience.org/library/papers/28676499PubMed
51849460cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor.Cell1991https://conductscience.org/library/papers/1849460PubMed
610196176Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase.J Biol Chem1999https://conductscience.org/library/papers/10196176PubMed
738565696Molecular basis for Gβγ-mediated activation of phosphoinositide 3-kinase γ.Nat Struct Mol Biol2024https://conductscience.org/library/papers/38565696PubMed
831135801The structural basis for Ras activation of PI3Kα lipid kinase.Phys Chem Chem Phys2019https://conductscience.org/library/papers/31135801PubMed
925533673PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Nat Rev Cancer2015https://conductscience.org/library/papers/25533673PubMed
1035022385Connexin 43 confers chemoresistance through activating PI3K.Oncogenesis2022https://conductscience.org/library/papers/35022385PubMed
1124459181The structural basis of PI3K cancer mutations: from mechanism to therapy.Cancer Res2014https://conductscience.org/library/papers/24459181PubMed
1225284480Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.Cancer Cell2014https://conductscience.org/library/papers/25284480PubMed
1318544649The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.Proc Natl Acad Sci U S A2008https://conductscience.org/library/papers/18544649PubMed
1425956158Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies.Mol Cancer Res2015https://conductscience.org/library/papers/25956158PubMed
1537623743STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.Cancer Discov2023https://conductscience.org/library/papers/37623743PubMed
1636243839An Overview of Class II Phosphoinositide 3-Kinases.Curr Top Microbiol Immunol2022https://conductscience.org/library/papers/36243839PubMed
1711136978Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma.Cell2000https://conductscience.org/library/papers/11136978PubMed
1825187123Idelalisib: first global approval.Drugs2014https://conductscience.org/library/papers/25187123PubMed
199182708Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin.Biochem J1997https://conductscience.org/library/papers/9182708PubMed
2016432180Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16432180PubMed

See all 166 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42764855Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478.Acta Pharm Sin B2026https://conductscience.org/library/papers/42764855PubMed
42738319PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability.Cancers (Basel)2026https://conductscience.org/library/papers/42738319PubMed
42621358Oncometabolites in Cancer Metabolism: Mechanistic Insights and Biomarker Potential- A Narrative Review.Health Sci Rep2026https://conductscience.org/library/papers/42621358PubMed
41754736The PI3K/AKT/NRF2 Signaling Pathway Involved in the Improvement of CUMS-Induced Depressive-like Behaviors by Apigenin.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/41754736PubMed
41239272Anoikis resistance and cancer.BMC Cancer2025https://conductscience.org/library/papers/41239272PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PIK3R15295PubTator's text mininghttps://conductscience.org/library/genes/5295

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39796708

GET https://conductscience.org/api/papers/v1/39796708/references?page=2